AIM Rongyu (Ningbo) Biopharmaceutical Co., Ltd. is a bio-pharmaceutical enterprise wholly owned by AIM Vaccine Co., Ltd. Established in 2001, it is a high and new technology enterprise recognized by Zhejiang Association for Science and Technology and Ningbo Association for Science and Technology.

Dedicated to the manufacturing and commercialization of rabies vaccine (Vero cell), AIM Rongyu has obtained the new drug certificate for rabies vaccine for human use (Vero cell) in 2001, the drug GMP certificate and drug production permit necessary for production in 2002, and the drug registration approval for freeze-dried rabies vaccine for human use (Vero cell) in September 2007. As for 2020, AIM Rongyu has been the second largest manufacturer of rabies vaccine for human use in China and the world. 

At the present stage, AIM Rongyu mainly produces freeze-dried rabies vaccine for human use with an annual production of about 22 million doses. Both its product quality and market occupancy are at the industry-leading level in China. Based on its rabies vaccine for human use (Vero cell), currently AIM Rongyu is developing two candidate rabies vaccines for human use. 

Under unified arrangement and planning by AIM Vaccine, AIM Rongyu is developing at a high speed. It always insists on putting product quality first, and remains dedicated to the R&D of new processes and new technologies. In the future, AIM Rongyu will strive to become China’s top-ranking viral vaccine manufacturer by developing and applying the most advanced production technologies.